Shopping Cart
- Remove All
Your shopping cart is currently empty
Belvarafenib
🥰Excellent
Catalog No. T5634Cas No. 1446113-23-0
Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM.
Belvarafenib
🥰Excellent
Purity: 99.62%
Catalog No. T5634Cas No. 1446113-23-0
Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $34 | In Stock | |
| 5 mg | $58 | In Stock | |
| 10 mg | $103 | In Stock | |
| 25 mg | $173 | In Stock | |
| 50 mg | $257 | In Stock | |
| 100 mg | $382 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $59 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Belvarafenib"
Sorafenib
Cited
Bay 43-9006
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
- $34
Size
QTY
CitedRegorafenib Cited
Fluoro-Sorafenib, BAY 73-4506
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
- $30
Size
QTY
CitedDabrafenib Cited
GSK2118436A, GSK2118436
T19031195765-45-7
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma.
- $41
Size
QTY
CitedRegorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
- $30
Size
QTY
Sorafenib tosylate Cited
Bay 43-9006
T0093475207-59-1
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
- $37
Size
QTY
CitedExarafenib
RAF/KIN_2787
T636442639957-39-2
Exarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.
- $131
Size
QTY
PLX-4720
PLX4720
T2473918505-84-7
PLX-4720 is a potent and selective B-Raf (V600E) inhibitor designed to block the ATP-binding site of oncogenic B-Raf with IC50 of 13 nM.
- $32
Size
QTY
Doramapimod
Cited
BIRB 796
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
- $31
Size
QTY
CitedVemurafenib Cited
RO5185426, RG7204, PLX4032
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
CitedGW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
- $51
Size
QTY
LY3009120
DP-4978
T68821454682-72-4
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 values of 44 nM for A-raf, 31-47 nM for B-Raf, and 42 nM for C-Raf in A375 cells. Phase 1.
- $30
Size
QTY
Sulindac sulfide
cis-Sulindac sulfide
T1303749627-27-2In house
Sulindac sulfide (cis-Sulindac sulfide) is a non-steroidal anti-inflammatory compound that has a high affinity for COX-1 and acts as an inhibitor in Ras activation of Raf-1. Sulindac sulfide is a non-competitive inhibitor of gamma-secretase with an IC50 value of 20.2 μM. It is an active metabolite of sulinic acid.
- $31
Size
QTY
Select Batch
Purity:99.62%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM. |
| Targets&IC50 | B-Raf (V600E):7 nM, B-Raf:56 nM, C-Raf:5 nM |
| In vitro | Belvarafenib (HM95573) inhibited B-RAF, B-RAFv600E and C-RAF with IC50 values of 56, 7 and 5 nM, respectively.[1] |
| In vivo | METHODS: Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023.EAP patients were treated with 450 mg of Belvarafenib (HM95573) twice daily. RESULTS Six patients with NRAS or RAF alterations were treated with Belvarafenib (HM95573), and 50% of the patients had control of their disease, including two patients with significant outcomes. [2] |
| Molecular Weight | 478.93 |
| Formula | C23H16ClFN6OS |
| Cas No. | 1446113-23-0 |
| Smiles | Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12 |
| Relative Density. | 1.562 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (52.2 mM)  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Belvarafenib | purchase Belvarafenib | Belvarafenib cost | order Belvarafenib | Belvarafenib chemical structure | Belvarafenib in vivo | Belvarafenib in vitro | Belvarafenib formula | Belvarafenib molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.